Intraocular Tuberculosis in Taiwan, a Long-Term Multicenter Retrospective Study
Purpose
This long-term multicenter retrospective study reviews the clinical manifestations, diagnostic tests, and treatment modalities of intraocular tuberculosis in Taiwan.
Methods
This retrospective chart review of patients with intraocular tuberculosis was conducted in China Medical University Hospital and other 10 hospitals (TUSG) from 2008/1/1~2017/12/31. We also use multiple regression model to analyze which factors will influence final BCVA.
Results
79 eyes of 51 patients were included. The mean age was 48.9 years. The mean change of LogMAR BCVA at last visit was -0.21 ± 0.45. The diagnostic tools included chest X-ray, chest CT, Mantoux test, interferon gamma release test, intraocular fluid TB PCR, and bronchial alveolar lavage. The clinical manifestations included 48 % posterior uveitis and 37 % panuveitis. 55 % cases were bilateral and 45 % unilateral. There were 60.76% retinal vasculitis, 35.44 % choroiditis, 21.52 % serpiginous-like choroiditis, 17.72 % vitreous hemorrhage, 12.66 % posterior synechiae, 6.33 % retinal detachment, 3.80% choroidal granuloma. The treatment modalities included 70.89% rifampicin, 68.35% isoniazid, 56.96% pyrazinamide, 50.63% ethambutol, 43.04% oral steroid, 19.83% posterior triamcinolone, 16.46% NSAIDs, 10.53% vitrectomy, and 4.11% immunosuppressants. The BCVA improved in 53.2 % eyes, remained stable in 32.9 % eyes, and worsened in 13.9 % eyes. In final model of multiple regression, worse initial BCVA, pyrazinamide, and receiving vitrectomy predicted better BCVA improvement. Ethambutol was associated with worse visual outcome.
Conclusion
This is the largest case review of intraocular tuberculosis in Taiwan to date. A prospective study is mandatory.
Conflict of interest
No
Author 1
Last name
LIN
Initials of first name(s)
CJ
City
Taichung
Country
Taiwan
Author 2
Last name
Hsia
Initials of first name(s)
NY
City
Taichung
Country
Taiwan
This website uses cookies to ensure you get the best experience on our website.
Learn more